🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huzhou
Clinical trial register · China

Clinical Trials in Huzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Hangzhou 373 Huzhou 16 Ningbo 15 Shanghai 13 Hanzhou 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine16 Eli Lilly and Company6 Yu jiren3 Novo Nordisk A/S2 Capital Medical University2 Clear sponsor filter
Site location
Hangzhou373 Huzhou16 Ningbo15 Shanghai13 Hanzhou13
All 69 locations
Target enrolment
to

Trials with a site in Huzhou

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD
NCT07665359Chronic Obstructive Pulmonary Disease (COPD)
DrugsTMP/SMX·Trimethoprim-sulfamethoxazole
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Not yet open
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07625514Gout Flare
DrugFirsekibart
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
264
Fuzhou, Hangzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-07
Not yet open
Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial
NCT07616531Gout Flares
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
118
Hangzhou, Fuzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-01
Not yet open
Effect of taVNS on Perioperative Anxiety in Major Abdominal Surgery
NCT07495163Perioperative Anxiety, Major Abdominal Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
282
Huzhou, Jiaxing, Meicheng, Hangzhou
2026-05-01
Not yet open
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
NCT07518810Multiple System Atrophy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
150
Nanning, Huzhou, Jiaxing, Ningbo, Taizhou, Beijing
2026-04-10
Recruiting
Ultrasound-Guided Intra-Articular vs Gluteal Intramuscular Corticosteroid Injection for Frozen Shoulder
NCT07416916Frozen Shoulder
DrugCompound betamethasone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
528
Shanghai, Hangzhou, Huzhou, Jinhua, Ningbo, Shanhu
2026-02-23
Recruiting
Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
NCT07114120Bronchiectasis, COPD
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
214
Hangzhou, Huzhou, Jinhua, Yueqing, Zhoushan
2025-07-14
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
NCT06375005Diffuse Cutaneous Systemic Sclerosis
DrugsMycophenolate Mofetil·Telitacicept
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
DrugVedolizumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Not yet open
Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction
NCT05994872Anterior Cruciate Ligament Injuries
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis
NCT06074679Cholecystectomy, Laparoscopic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
600
Huangshan City, Hangzhou, Huzhou, Lishui, Meicheng
2023-10-01
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
NCT05742425Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type
DrugSerplulimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Huzhou
2023-03
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/huzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Huzhou that also match the filters currently applied.

How many clinical trials are recruiting in Huzhou?

7 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huzhou), 16 studies
PhaseStudiesRecruitingShare
Not applicable9156.3%
Phase 23318.8%
Phase 43318.8%
Phase 2/3106.3%

Most active sponsors

Lead sponsors with the most studies (Huzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine167
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.